Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for bioAffinity Technologies, Inc. (BIAF : NSDQ)

• Company Description    bioAffinity Technologies Inc. is a cancer diagnostics company which develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer. bioAffinity Technologies Inc. is based in SAN ANTONIO. Number of Employees: 57

• Price / Volume Information    Yesterday's Closing Price: $1.51 Daily Weekly Monthly 20 Day Moving Average: 84,389 shares Shares Outstanding: 4.50 (millions) Market Capitalization: $6.79 (millions) Beta: 2.41 52 Week High: $38.70 52 Week Low: $1.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.68% -20.74% 12 Week -70.26% -71.12% Year To Date -94.47% -94.82%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3300 NACOGDOCHES ROAD SUITE 216 - SAN ANTONIO,TX 78217 USA ph: 210-698-5334 fax: - biaf@redchip.com http://www.bioaffinitytech.com

• General Corporate Information    Officers Maria Zannes - President; Chief Executive Officer; and Director Steven Girgenti - Executive Chairman and Director J. Michael Edwards - Chief Financial Officer Robert Anderson - Director Stuart Diamond - Director Peer Information bioAffinity Technologies, Inc. (CORR.) bioAffinity Technologies, Inc. (RSPI) bioAffinity Technologies, Inc. (CGXP) bioAffinity Technologies, Inc. (BGEN) bioAffinity Technologies, Inc. (GTBP) bioAffinity Technologies, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09076W307 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/30/26 Share - Related Items Shares Outstanding: 4.50 Most Recent Split Date: 9.00 (0.03:1) Beta: 2.41 Market Capitalization: $6.79 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/30/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.76 Price/Cash Flow: - Price / Sales: 1.00 EPS Growth vs. Year Ago Period: 43.81% vs. Previous Quarter: 30.84% Sales Growth vs. Year Ago Period: -38.47% vs. Previous Quarter: 13.86% ROE 09/30/25 - -425.87 06/30/25 - -845.68 03/31/25 - -367.64 ROA 09/30/25 - -162.30 06/30/25 - -181.92 03/31/25 - -154.15 Current Ratio 09/30/25 - 3.65 06/30/25 - 0.64 03/31/25 - 0.55 Quick Ratio 09/30/25 - 3.64 06/30/25 - 0.63 03/31/25 - 0.53 Operating Margin 09/30/25 - -169.76 06/30/25 - -138.32 03/31/25 - -110.53 Net Margin 09/30/25 - -217.45 06/30/25 - -152.16 03/31/25 - -110.53 Pre-Tax Margin 09/30/25 - -216.86 06/30/25 - -151.64 03/31/25 - -110.35 Book Value 09/30/25 - 1.98 06/30/25 - -2.25 03/31/25 - 2.37 Inventory Turnover 09/30/25 - 134.32 06/30/25 - 158.76 03/31/25 - 190.19 Debt-to-Equity 09/30/25 - 0.01 06/30/25 - - 03/31/25 - 0.27 Debt-to-Capital 09/30/25 - 0.51 06/30/25 - - 03/31/25 - 21.07

Powered by Zacks Investment Research ©